Teva Pharmaceutical Industries Limited

Rakefet Cohen

Michael Fox

Muhammad Safadi

Sasson Habbah

Minutza Leibovici

Anne Braunstein

The patent provides a process of preparing a pharmaceutical preparation of glatiramer acetate and mannitol in a suitable container comprising the steps of: This patent further provides an aqueous pharmaceutical solution comprising 40 mg/ml glatiramer acetate and 40 mg/ml mannitol, wherein the aqueous pharmaceutical solution This patent also provides a prefilled syringe, an automated injector and a method of treatment of a human patient.

Process for manufacturing glatiramer acetate product

Provided are formulations of a stable commercial paroxetine tablet comprising paroxetine hydrochloride anhydrous, povidone, copovidone or HPMC as a binder, and an HCl free/non-hygroscopic filler, prepared by the wet granulation method.

Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof

Provided are formulations of a stable paroxetine hydrochloride tablet comprising paroxetine hydrochloride, povidone or copovidone as a binder, and an HCl free/non-hygroscopic filler, prepared by the wet granulation method. Preferably, the paroxetine hydrochloride is paroxetine hydrochloride hemihydrate.

Growing community of inventors

Kokhav Ya'ir-Tzur Yigal, Israel

Rakefet Cohen